Congressman Chaka Fattah Meets with Amarantus to Discuss Brain Research

Congressman Chaka Fattah Meets with Amarantus to Discuss Brain Research
Congressman Chaka Fattah recently met with Amarantus, a biotechnology firm specializing in discovering and developing treatments and diagnostics for Alzheimer's disease and other degenerative brain conditions, to discuss ongoing and future neurologic research strategies. Gerald Commissiong, the CEO of Amarantus, and Robert Farrell, the CFO, had briefed Congressman Fattah on a newly-signed contract between the company and Georgetown University for 6 patent rights covering serological biomarkers for Alzheimer's disease. These rights are jointly owned by the University of Rochester and Georgetown. Congressman Fattah explained in a press release: "I continue to be impressed by the advanced research happening within the neuroscience field. This new agreement is an important milestone in Alzheimer's diagnostic development with the potential to help recognize individuals who may be at-risk for Alzheimer's and ultimately develop the information necessary to better detect and diagnose the disease. Through the Fattah Neuroscience Initiative, I look forward to continuing to work with public and private entities to ensure our country is focused on the research and development that will lead to breakthroughs in the field." The relevance of genomic testing in the timely and effective management of Alzheimer's disease, and the constantly growing need for increased federal commitment to support research and development on the disease were also underscored during the briefing. According to Congressman Chaka Fattah's office, Alzheimer's disease is ranked third among the leading causes of death in the United States. More than 5.4 million people suffer from this neurodegenerative disease, and this number is predicted to increase along with the climb i
Subscribe or to access all post and page content.